Skip to content
Menu

Vir Biotechnology, Inc. VIR

Full chart Compare
Set alert

Price alert · VIR

All alert types
8.39 USD -0.48 (-5.41%)

Regular-session close

8.43 +0.04 +0.48%

After hours · Nov 20, 6:48 PM ET

8.34 Day range 8.92
5.45 52-week range 14.38
YTD
+39.14%
1 year
+50.90%

5D -3.38 (-25.30%)

1012TueWedThuFriMon9.98
Market cap
1.56B
Revenue (ttm)
302.80M
Profit margin
-61.03%
EPS (ttm)
-1.18
Shares out
186.27M
Forward P/E
-3.54
YTD return
+39.14%
1-year return
+50.90%
50-day average
11.00
200-day average
9.80
Volume
3.09M
Avg volume
2.43M
Open
8.81
Previous close
8.87
Day's range
8.34 – 8.92
52-week range
5.45 – 14.38
Beta
1.74
Analysts
Strong Buy
Price target
23.13 (+175.6%)
Earnings date
Feb 22, 2027

Key statistics

Enterprise value
1.15B
Price / sales
5.16
Price / book
1.59
Free cash flow
-81.92M
Total cash
458.36M
Total debt
90.78M
Return on equity
-21.84%
Short % of float
9.97%

Fundamental scorecard

7 of 25 checks passed on VIR’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
VIR Revenue — quarterly -188.00K
VIR Net income — quarterly -96.25M
VIR EPS — quarterly -0.57

Earnings

VIR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 22, 2027Dec 30, 2026-0.11874———
Nov 4, 2026Sep 30, 2026-0.77042-0.57+0.20+26.01%
Aug 5, 2026Jun 30, 20260.33260.47+0.14+41.31%
May 6, 2026Mar 31, 2026-0.01-0.85-0.84-8,400.00%
Feb 23, 2026Dec 31, 2025-0.42-0.31+0.11+26.19%
Nov 5, 2025Sep 30, 2025-0.70-1.17-0.47-67.14%

Upgrades / downgrades

VIR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026Morgan StanleymainOverweightOverweight
Nov 10, 2026Evercore ISI GroupmainOutperformOutperform
Nov 9, 2026HC Wainwright & Co.reitBuyBuy
Nov 9, 2026NeedhammainBuyBuy
Nov 5, 2026NeedhammainBuyBuy
Oct 7, 2026HC Wainwright & Co.mainBuyBuy

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
vir.bio

News

Your note

Sign in to keep a note on VIR — it syncs with the Stock Master app.

Insider holders

VIR insider holders
InsiderRelationLatest transactionDateShares held
DE BACKER MARIANNEChief Executive OfficerSaleApr 5, 20261,001,260
DE VERNEUIL VANINA ALEXANDRA HUARDGeneral CounselSaleNov 2, 2026110,193
EISNER MARK EOfficerSaleFeb 24, 2026154,024
HANLY ANN MChief Technology OfficerSaleFeb 23, 2025117,901
MORE ROBERT JDirectorStock Award(Grant)May 26, 2026558,573
O'BYRNE JASONChief Financial OfficerSaleFeb 23, 2026162,615

Institution ownership

VIR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.13.11%22,448,921188.35MSep 29, 2026
Arch Venture Management, Llc7.41%12,694,163106.50MSep 29, 2026
Vanguard Portfolio Management LLC7.02%12,024,354100.88MSep 29, 2026
SB Investment Advisers (UK) LTD6.39%10,948,09391.85MSep 29, 2026
GSK plc4.99%8,550,95471.74MSep 29, 2026
State Street Corporation4.57%7,822,78165.63MSep 29, 2026

Fund ownership

VIR fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.83%4,846,94840.67MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.06%3,533,09229.64MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.03%3,476,66929.17MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.49%2,546,14421.36MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.17%1,996,62516.75MJun 29, 2026
VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund1.03%1,762,41214.79MJun 29, 2026